These findings were independently validated using immunohistochemistry for CD8+ T-cells in 80 patient neuroblastoma samples, which showed that the increased CD8+ T-cell scores are significantly higher in MYCN-NA tumors compared to MYCN-A tumors (Figures 2C and 2D). This evidence concerns the gene CD8A and neuroblastoma.